๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Prostate Cancer
Clinical trial register · China

Prostate Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 41 Nanjing 23 Guangzhou 18 Shanghai 18 Wuhan 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking University First Hospital12 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6 Jiangsu HengRui Medicine Co., Ltd.6 AstraZeneca5 Pfizer4
Site location
Beijing41 Nanjing23 Guangzhou18 Shanghai18 Wuhan14
All 59 locations
Target enrolment
to

Prostate Cancer trials in China

112 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
NCT07830212Prostatic Neoplasms, Prostate Cancer
Drug[68Ga]Ga-OncoACP3
Yong He
Phase 2
50
Wuhan
2026-10
Recruiting
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
NCT07542379Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1
13
Wuxi
2026-08-31
Recruiting
This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
NCT07649122Prostate Cancer
Norroy Bioscience Co., LTD
Phase 3
232
Nanjing, Wuxi
2026-08-31
Recruiting
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
NCT07735377Prostate Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
118
Guangzhou
2026-08-26
Recruiting
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
NCT07711184Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
320
Shanghai
2026-07-30
Recruiting
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
NCT07795723Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
454
Nanjing
2026-07-20
Recruiting
MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology
NCT07694752Urethral Internal Sphincter Morphology, Benign Prostatic Hyperplasia, Prostate Cancer
Jiangsu Taizhou People's Hospital
Observational
80
Taizhou
2026-07-15
Not yet open
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
NCT07677566Prostate Cancer, Prostate Cancer Patients
DrugsPluvicto·Darolutamide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4
20
Nanjing
2026-07-01
Not yet open
Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery
NCT07690462Prostate Cancer
Xiangya Hospital of Central South University
Observational
120
Changsha
2026-07
Recruiting
Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports
NCT07707232Prostate Cancer
First Affiliated Hospital of Wenzhou Medical University
Observational
4,600
Wenzhou
2026-06-17
Recruiting
A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
NCT07689656Prostate Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
50
Wuhan
2026-06-08
Not yet open
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
NCT07310433Prostate Cancer, Metastatic Prostate Cancer
DrugDapagliflozin
Yung NA
Phase 2
60
Shanghai
2026-06-01
Recruiting
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
NCT07567521Prostate Cancer
C Ray Therapeutics
Phase 1/2
90
Taiyuan, Shanghai
2026-05-22
Not yet open
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
NCT07468396Prostate Cancer
Gan & Lee Pharmaceuticals.
Phase 1
65
Beijing
2026-04-30
Recruiting
Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07562438Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
20
Fuzhou
2026-04-29
Recruiting
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
NCT07407283Prostate Cancer
DrugsHRS-5041·Tazemetostat·Rezvilutamide
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Chengdu, Tianjin
2026-04-08
Not yet open
Darolutamide ยฑ ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
NCT07476677Prostate Cancer
DrugDarolutamide
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Beijing
2026-04-01
Not yet open
A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery
NCT07480044Postoperative Delirium (POD), Prostate Cancer, Kidney Tumor
Zhejiang University
Not applicable
220
Hangzhou
2026-03-20
Recruiting
The Dosimetry, Safety and Diagnostic Efficacy of โถโธGa-FC516 in Healthy Subjects and Patients With Prostate Cancer
NCT07468708Healthy Adult, Prostate Cancer
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1
10
Guangzhou
2026-03-09
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Active, closed
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
NCT07236112Prostate Cancer
C Ray Therapeutics
Phase 1
6
Wuhan, Jinan
2026-02-08
Recruiting
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446Prostate Cancer
DrugSaruparib
AstraZeneca
Phase 1/2
300
Chengdu
2026-01-27
Recruiting
Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
NCT07112599Prostate Cancer, Lymph Node Cancer Metastatic, Artificial Intelligence (AI)
Anhui Medical University
Observational
2,000
Hefei
2026-01-25
Recruiting
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
NCT07339267Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsASP5541·Prednisone
Astellas Pharma Global Development, Inc.
Phase 1
12
Beijing
2026-01-20
Not yet open
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
NCT07311915Prostate Cancer
DrugPropranolol
Zhongda Hospital
Not applicable
30
Nanjing
2026-01-15
Recruiting
A Phase I Trial of A-CAR032 in Participants With mCRPC
NCT07344311Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
Shanghai AbelZeta Ltd.
Phase 1
27
Beijing, Wuhan, Xuzhou, Hangzhou
2026-01-13
Not yet open
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07381582Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1
15
Beijing, Mianyang
2026-01-01
Active, closed
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer
NCT07597369Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Cancer (mCRPC)
Peking University First Hospital
Observational
1,600
Beijing
2026-01-01
Not yet open
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
NCT07282197Prostate Cancer
DrugDarolutamide
Peking University First Hospital
Phase 2
40
Beijing
2026-01
Not yet open
PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial
NCT07272317Prostate Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
98
Shanghai
2025-12-15
Recruiting
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106Prostate Cancer
DrugsHS-20093·Zeprumetostat·Abiraterone·Enzalutamide
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Active, closed
Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer
NCT06434649Surgical Procedure, Unspecified, Prostate Cancer
Ning Xu
Not applicable
118
Fuzhou
2025-11-01
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
68Ga-XACP3 PET/CT in Prostate Cancer
NCT07242014Prostate Cancer, PET/CT, ACP3
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2025-09-01
Not yet open
Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
NCT05576766Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol, Prehabilitation
Peking University First Hospital
Not applicable
54
Beijing
2025-09
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsASP5541·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Yangzhou, Tianjin, Hangzhou, Huaian, Shanghai
2025-08-19
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogramโ‰ฅ7%
NCT07115992Prostate Cancer, Prostate Adenoma
Ruijin Hospital
Not applicable
270
Shanghai
2025-07-30
Recruiting
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
NCT07172685Prostate Cancer
Qilu Hospital of Shandong University
Not applicable
116
Jinan
2025-07-30
Active, closed
AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP๏ผ‰
NCT07082049Prostate Cancer
Fudan University
Not applicable
160
Shanghai
2025-07-27
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Active, closed
Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy
NCT05761912Prostate Cancer, Ultrasound, Radiomics
Shanghai Minhang Central Hospital
Observational
464
Shanghai
2025-06-23
Recruiting
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
NCT07149831Prostate Cancer
DrugFlotufolastat F-18
Sinotau Pharmaceutical Group
Phase 1
6
Beijing
2025-06-07
Active, closed
AI Multimodal Model for Predicting CRPC Progression Risk
NCT07658573Prostate Cancer, Castration-Resistant Prostate Cancer
Guangxi Medical University
Observational
500
Nan'ning
2025-06-01
Recruiting
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
NCT07015138Prostate Cancer, Oligometastatic Prostate Cancer
Peking University First Hospital
Not applicable
390
Beijing
2025-06-01
Not yet open
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
NCT06901492PSMA PET/CT, Prostate Cancer, MpMRI
Nanjing First Hospital, Nanjing Medical University
Not applicable
120
Nanjing
2025-06-01
Recruiting
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Changsha, Hangzhou, Beijing
2025-05-15
Recruiting
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
NCT06970119Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 1/2
55
Wuxi, Tianjin
2025-05-14
Active, closed
The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer
NCT06824259Prostate Cancer
Peking University First Hospital
Not applicable
400
Beijing
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
NCT07552285Prostate Cancer, Prostate Cancer (Diagnosis)
The First Affiliated Hospital of Soochow University
Observational
300
Suzhou
2025-05-01
Active, closed
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07117760Prostate Cancer
Drugs225Ac-LNC1011·68Ga-PSMA-11
First Affiliated Hospital of Fujian Medical University
Phase 1/2
16
Fuzhou
2025-04-22
Recruiting
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
NCT07163910Prostate Cancer
DrugHomoharringtonine
baotai Liang
Phase 2
93
Nanjing
2025-04-20
Recruiting
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07363486Prostate Cancer
Drug225Ac-LNC1011
First Affiliated Hospital of Fujian Medical University
Phase 1/2
9
Fuzhou
2025-04-01
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou, Shantou, Ganzhou
2025-04-01
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer
NCT07115277Prostate Cancer
DrugFlotufolastat F-18
Sinotau Pharmaceutical Group
Not applicable
121
Beijing
2025-03-14
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions
NCT06841211Prostate Cancer
Peking University First Hospital
Not applicable
572
Beijing
2025-02-01
Recruiting
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
NCT06783829Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
240
Chengdu
2025-01-22
Recruiting
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
NCT06754085Prostate Cancer
HTA Co., Ltd.
Phase 3
131
Guangzhou
2024-12-19
Recruiting
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
NCT06756334Prostate Cancer, PET/CT
Anhui Provincial Hospital
Phase EARLY_PHASE1
30
Hefei
2024-12-19
Recruiting
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
NCT06689163Prostate Cancer
DrugsAbiraterone Acetate ๏ผˆII๏ผ‰·HRS-1167·Prednisone Acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
66
Hefei, Changsha
2024-12-11
Recruiting
The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer
NCT06737588Prostate Cancer
Anhui Provincial Hospital
Observational
600
Hefei, Wuhu
2024-12-01
Recruiting
Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer
NCT06684652Prostate Cancer
Peking University First Hospital
Not applicable
300
Beijing
2024-12-01
Not yet open
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
NCT06662708Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
Shao Pengfei
Not applicable
200
Nanjing
2024-12-01
Recruiting
Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
NCT06612047Prostate Cancer
Anhui Provincial Hospital
Observational
150
Hefei
2024-10-08
Recruiting
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
NCT06696326Positron-Emission Tomography(PET), Prostate Cancer, Trophoblast Cell Surface Antigen 2
The First Affiliated Hospital of Xiamen University
Not applicable
100
Xiamen
2024-10-01
Recruiting
Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer
NCT06584279Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
563
Nanjing
2024-10
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094Prostate Cancer
DrugsAbiraterone Acetate ๏ผˆII๏ผ‰·HRS-6208·HRS-2189·HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
100
Harbin, Shanghai
2024-09-25
Recruiting
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
NCT06663007Prostate Cancer, CDK12 Gene Mutation
DrugsEnvafolimab·Disitamab Vedotin
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
NCT07250542Prostate Cancer
DrugFasudil Hydrochloride
baotai Liang
Phase 2
30
Nanjing
2024-07-05
Recruiting
Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer
NCT06482645Prostate Cancer
Peking University First Hospital
Not applicable
640
Beijing
2024-07-01
Recruiting
A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients
NCT06469710Prostate Cancer, Circulating Tumor Cell, Leukapheresis
RenJi Hospital
Observational
50
Shanghai
2024-06-25
Not yet open
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study
NCT06435702Prostate Cancer
Peking University Third Hospital
Observational
108
Beijing
2024-06-01
Recruiting
Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis
NCT06392737Prostate Cancer
Peking University First Hospital
Not applicable
360
Beijing
2024-05-01
Recruiting
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
NCT06575257Prostate Cancer
DrugsGoserelin·Darolutamide
Xijing Hospital
Phase 2
80
Xiโ€™an
2024-05-01
Recruiting
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
NCT06335693Prostate Cancer
Changhai Hospital
Not applicable
9
Shanghai
2024-03-28
Recruiting
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
NCT06306612Prostate Cancer
RenJi Hospital
Not applicable
192
Shanghai
2024-03-21
By invitation
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
NCT06723665Prostate Cancer
Drugs18F-PSMA-1007·Fluorodeoxyglucose
Affiliated Hospital of Jiangnan University
Not applicable
50
Wuxi
2024-01-25
Recruiting
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
NCT07319923Prostate Cancer, Community-based Screening
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Recruiting
The Development and Validation of MRI-AI-based Predictive Models for csPCa
NCT06842264Prostate Cancer
Peking University First Hospital
Observational
3,000
Beijing
2024-01-01
Active, closed
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
NCT06183905PROSTATE CANCER, Prostate Biopsy
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
635
Shanghai
2023-12-29
Recruiting
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575Prostate Cancer
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832Prostate Cancer, Biochemical Recurrence
DrugRezvilutamide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
102
Nanjing
2023-09-07
Recruiting
High Resolution Diffusion Weighted Imaging in Prostate
NCT06636747Prostate Cancer, Prostate Disease
The First Affiliated Hospital with Nanjing Medical University
Observational
500
Nanjing
2023-08-01
Not yet open
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
NCT05778097Prostate Cancer, Biochemical Recurrence, High Risk
DrugApalutamide Tab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
103
Nanjing, Nantong
2023-04-01
Recruiting
CART-PSMA Cells for Advanced Prostate Cancer
NCT05656573Prostate Cancer
Nova Therapeutics LLC
Phase 1
20
Beijing
2023-03-01
Recruiting
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT05753566Prostate Cancer, Biochemical Recurrence
DrugRezvilutamide
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
96
Nanjing
2023-03
Recruiting
Safety and Efficacy of Two-step Radical Prostatectomy
NCT05722392Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2023-02-15
Recruiting
99mTc-P137 SPECT/CT in Prostate Cancer
NCT05672485Prostate Cancer
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
40
Xi'an
2023-01-05
Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and ฮฑvฮฒ3 Positive Tumor Patients
NCT05549024Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
DrugFluorodeoxyglucose
Peking Union Medical College Hospital
Phase EARLY_PHASE1
90
Beijing
2022-08-16
Recruiting
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
NCT05324332Prostate Cancer
Drug68Ga-PSMA-11
Peking Union Medical College Hospital
Not applicable
50
Beijing
2022-04-15
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
DrugsTalazoparib·Enzalutamide
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
By invitation
Plasma Exosome RNA to Diagnose Prostate Cancer
NCT06604130Prostate Cancer
Xijing Hospital
Not applicable
1,600
Lanzhou, Yinchuan, Xining, Weinan, Xi'an, Xianyang, Yanโ€™an
2021-03-12
Recruiting
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NCT05183074Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2021-02-01
Rows per page Showing 1–100 of 112
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/prostate-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 112 of those studies listing the condition Prostate Cancer.

How many Prostate Cancer trials are recruiting in China?

75 of the 112 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 17 have not yet opened recruitment, 18 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Prostate Cancer), 112 studies
PhaseStudiesRecruitingShare
Not applicable281625%
Observational221619.6%
Phase 2171015.2%
Phase 1131111.6%
Phase 1/2131111.6%
Phase 31169.8%
Phase EARLY_PHASE1544.5%
Phase 2/3211.8%
Phase 4100.9%

Most active sponsors

Lead sponsors with the most studies (Prostate Cancer)
Lead sponsorStudiesRecruiting
Peking University First Hospital128
Jiangsu HengRui Medicine Co., Ltd.66
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School64
AstraZeneca53
Pfizer41
Anhui Provincial Hospital33
Astellas Pharma Global Development, Inc.32
First Affiliated Hospital of Fujian Medical University32
Peking Union Medical College Hospital32
RenJi Hospital33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.